Adaptive Biotechnologies Announces New Clinical Data Demonstrating Impact of clonoSEQ® Assay on Patients with Blood Cancers at the 62nd ASH Annual Meeting
December 06, 2020 10:00 ET
|
Adaptive Biotechnologies
SEATTLE, Dec. 06, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
Adaptive Biotechnologies and Collaborators to Present Data from More Than 35 Abstracts at ASH 2020 Highlighting Clinical Relevance of MRD Testing with the clonoSEQ® Assay in Blood Cancer Patients
November 23, 2020 08:00 ET
|
Adaptive Biotechnologies
Studies reinforce clonoSEQ as standard of care in minimal residual disease (MRD) across eight disease statesReal-world evidence shows treatment decisions based on precise MRD measurement directly...
Preliminary Data from Real-World Study Demonstrate T-cell Testing Outperforms Antibody Testing in Identifying Past SARS-CoV-2 Infections
November 13, 2020 08:00 ET
|
Adaptive Biotechnologies
– Findings support upcoming launch of T-Detect™ COVID, first T-cell test for novel coronavirus– Data support mounting evidence that measuring T-cells is necessary to fully characterize immune...
Adaptive Biotechnologies Announces Collaboration with GSK to Measure Minimal Residual Disease with clonoSEQ® Assay Across its Hematology and Oncology Portfolio
November 10, 2020 16:13 ET
|
Adaptive Biotechnologies
SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
Adaptive Biotechnologies Reports Third Quarter 2020 Financial Results
November 10, 2020 16:10 ET
|
Adaptive Biotechnologies
SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...
Adaptive Biotechnologies to Report Third Quarter Financial Results on November 10, 2020
October 13, 2020 16:05 ET
|
Adaptive Biotechnologies
SEATTLE, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
Adaptive Biotechnologies to Present at the Morgan Stanley 2020 Healthcare Conference
September 01, 2020 16:03 ET
|
Adaptive Biotechnologies
SEATTLE, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
Adaptive Biotechnologies Reports Second Quarter 2020 Financial Results
August 10, 2020 16:05 ET
|
Adaptive Biotechnologies
SEATTLE, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...
Adaptive Biotechnologies to Present at the UBS Genomics 2.0 and Medtech Innovations Summit
August 10, 2020 08:05 ET
|
Adaptive Biotechnologies
SEATTLE, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune...
Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess Minimal Residual Disease (MRD) in Patients with Chronic Lymphocytic Leukemia
August 06, 2020 09:24 ET
|
Adaptive Biotechnologies
First and only FDA-cleared assay for MRD in CLL, multiple myeloma and ALLCLL clearance includes testing in blood; Adaptive collaborating with LabCorp® and Phlebotek Solutions® to provide clonoSEQ...